Due to a limited supply, we are unable to accept phone calls to schedule COVID-19 vaccinations.
For the most up-to-date information, please check our COVID-19 Vaccination Website.

 

Additional Coronavirus Updates >

MENU

Fox Chase Cancer Center Welcomes Cihangir Duy

January 26, 2021

PHILADELPHIA (January 26, 2021) – Fox Chase Cancer Center announces the hiring of Cihangir Duy, PhD, MS, who has joined the Cancer Signaling and Epigenetics Program as an assistant professor.

“We are thrilled to have Dr. Duy join our program. He has made critical discoveries that inform how we can leverage epigenetic therapies to tackle hematologic malignancies,” said Johnathan Whetstine, PhD, the epigenetics program’s leader.

Before coming to Fox Chase, Duy was an instructor in cell and developmental biology at Weill Cornell Medicine Graduate School of Medical Sciences in New York City. He completed his postdoctoral studies at Weill Cornell Medicine, where he studied the epigenome and organoids. Duy recently received a grant from the Alternatives Research & Development Foundation to further develop these organoid models.

He carried out his doctoral studies in cancer biology and immunology at the University of Southern California and graduated summa cum laude from the University of Düsseldorf in Germany, where he received his MS degree. Duy’s thesis included the Philadelphia chromosome, which was discovered at Fox Chase in 1959.

Duy was awarded a postdoctoral fellowship by the Leukemia and Lymphoma Society. The William Guy Forbeck Research Foundation recently selected Duy as a Forbeck Scholar. This prestigious appointment recognizes early career cancer researchers for their achievements, research, and dedication to the field.

The Hospital of Fox Chase Cancer Center and its affiliates (collectively “Fox Chase Cancer Center”), a member of the Temple University Health System, is one of the leading cancer research and treatment centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence five consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship and community outreach. It is the policy of Fox Chase Cancer Center that there shall be no exclusion from, or participation in, and no one denied the benefits of, the delivery of quality medical care on the basis of race, ethnicity, religion, sexual orientation, gender, gender identity/expression, disability, age, ancestry, color, national origin, physical ability, level of education, or source of payment.

 

For more information, call 888-369-2427

Connect with Fox Chase